MX2021002017A - Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. - Google Patents

Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.

Info

Publication number
MX2021002017A
MX2021002017A MX2021002017A MX2021002017A MX2021002017A MX 2021002017 A MX2021002017 A MX 2021002017A MX 2021002017 A MX2021002017 A MX 2021002017A MX 2021002017 A MX2021002017 A MX 2021002017A MX 2021002017 A MX2021002017 A MX 2021002017A
Authority
MX
Mexico
Prior art keywords
disorders
roluperidone
negative symptoms
neuroplasticity
treat negative
Prior art date
Application number
MX2021002017A
Other languages
English (en)
Inventor
Remy Henri Luthringer
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of MX2021002017A publication Critical patent/MX2021002017A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud se refiere al uso de roluperidona, es decir, Compuesto (I): (ver Fórmula) y sales, solvatos, composiciones farmacéuticas y formas de dosificación del mismo, para su uso en métodos de tratamiento de síntomas y trastornos negativos (por ejemplo, trastornos del autismo, ambliopía, trastornos de la personalidad, lesión cerebral traumática), así como para aumentar la neuroplasticidad y promover la neuroprotección en sujetos que lo necesitan.
MX2021002017A 2018-08-21 2019-08-21 Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. MX2021002017A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720667P 2018-08-21 2018-08-21
US201962831535P 2019-04-09 2019-04-09
PCT/US2019/047555 WO2020041504A1 (en) 2018-08-21 2019-08-21 Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Publications (1)

Publication Number Publication Date
MX2021002017A true MX2021002017A (es) 2021-04-28

Family

ID=67874530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002017A MX2021002017A (es) 2018-08-21 2019-08-21 Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.

Country Status (14)

Country Link
US (2) US11083723B2 (es)
EP (1) EP3840835A1 (es)
JP (1) JP2022511266A (es)
KR (1) KR20210061349A (es)
CN (1) CN112955219A (es)
AU (1) AU2019326525A1 (es)
BR (1) BR112021002654A2 (es)
CA (1) CA3108882A1 (es)
CL (2) CL2021000424A1 (es)
GB (1) GB2591667A (es)
IL (1) IL280765A (es)
MA (1) MA53437A (es)
MX (1) MX2021002017A (es)
WO (1) WO2020041504A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20171646A1 (es) 2014-12-02 2017-11-13 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
PE20200732A1 (es) 2017-06-21 2020-07-23 Minerva Neurosciences Inc Formas de dosificacion oral y de liberacion controlada gastrorresistentes
MA53437A (fr) * 2018-08-21 2021-06-30 Minerva Neurosciences Inc Utilisation de rolupéridone pour traiter des symptômes et des troubles négatifs, augmenter la neuroplasticité et favoriser la neuroprotection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
EP0497843A4 (en) 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
US7166617B2 (en) 2000-02-29 2007-01-23 Mitsubishi Pharma Corporation Cyclic amide derivatives
DOP2006000125A (es) 2005-06-06 2006-12-31 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US9090707B2 (en) 2010-01-27 2015-07-28 Children's Medical Center Corporation Pro-angiogenic fragments of prominin-1 and uses thereof
ES2914120T3 (es) 2010-07-20 2022-06-07 Minerva Neurosciences Inc Procedimientos de uso de derivados de amida cíclicos para tratar trastornos mediados por el receptor sigma
BR112013001303A2 (pt) * 2010-07-20 2016-05-17 Cyrenaic Pharmaceuticals Inc métodos de uso de derivados de amida cíclica para tratar esquizofrenia
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP2014508187A (ja) 2011-03-17 2014-04-03 ルピン・リミテッド 選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
PE20171646A1 (es) * 2014-12-02 2017-11-13 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
KR20240005110A (ko) 2016-05-25 2024-01-11 미쓰비시 타나베 파마 코퍼레이션 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법
PE20200732A1 (es) 2017-06-21 2020-07-23 Minerva Neurosciences Inc Formas de dosificacion oral y de liberacion controlada gastrorresistentes
MA53437A (fr) * 2018-08-21 2021-06-30 Minerva Neurosciences Inc Utilisation de rolupéridone pour traiter des symptômes et des troubles négatifs, augmenter la neuroplasticité et favoriser la neuroprotection

Also Published As

Publication number Publication date
WO2020041504A1 (en) 2020-02-27
GB2591667A (en) 2021-08-04
AU2019326525A1 (en) 2021-03-04
MA53437A (fr) 2021-06-30
EP3840835A1 (en) 2021-06-30
US20200061046A1 (en) 2020-02-27
US20220096455A1 (en) 2022-03-31
US11083723B2 (en) 2021-08-10
GB202103819D0 (en) 2021-05-05
BR112021002654A2 (pt) 2021-05-04
CN112955219A (zh) 2021-06-11
CL2021000424A1 (es) 2021-07-09
CL2023001580A1 (es) 2023-11-03
KR20210061349A (ko) 2021-05-27
CA3108882A1 (en) 2020-02-27
IL280765A (en) 2021-04-29
JP2022511266A (ja) 2022-01-31

Similar Documents

Publication Publication Date Title
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
CR20210335A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular la hemoglobina
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
MY190408A (en) Compositions and methods for treating cns disorders
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MY166557A (en) Quinazoline derivatives for the treatment of viral infections and further diseases
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
MX2021002017A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
PH12021550872A1 (en) Therapeutic compounds
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
WO2018154118A3 (en) Aromatic compounds which enhance notch signaling, for use in therapy
MX2021002322A (es) Nuevos metodos.
MX2021004860A (es) Piridazinas novedosas.
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
CR20230177A (es) Compuestos y composiciones como moduladores de señalización tlr
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
MX2021006209A (es) Montelukast para el tratamiento de la osteoartritis erosiva de la mano.